(Q30827022)

English

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 June 2017

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years (English)

1 reference

Europe PubMed Central

26 June 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

5

object named as

M von Eynatten

1 reference

Europe PubMed Central

26 June 2017

author name string

G Schernthaner

1

1 reference

Europe PubMed Central

26 June 2017

A H Barnett

2

1 reference

Europe PubMed Central

26 June 2017

S Patel

3

1 reference

Europe PubMed Central

26 June 2017

U Hehnke

4

1 reference

Europe PubMed Central

26 June 2017

H-J Woerle

6

1 reference

Europe PubMed Central

26 June 2017

publication date

3 July 2014

1 reference

Europe PubMed Central

26 June 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

26 June 2017

16

1 reference

Europe PubMed Central

26 June 2017

11

1 reference

Europe PubMed Central

26 June 2017

1078-1086

1 reference

Europe PubMed Central

26 June 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Assessment of barriers to improve diabetes management in older adults: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Increased mortality of patients with diabetes reporting severe hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Hypoglycemia and cardiovascular risks

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diab

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Emergency hospitalizations for adverse drug events in older Americans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Diabetes-related morbidity and mortality in a national sample of U.S. elders.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Diabetes in older adults

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Frequent hypoglycemia among elderly patients with poor glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12321

21 January 2018

Identifiers

10.1111/DOM.12321

1 reference

Europe PubMed Central

26 June 2017

1 reference

Europe PubMed Central

26 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30827022&oldid=1604041858"